Analyst's Disclosure: I/we have a beneficial long position in the shares of SAM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any in ...

On Holding (ONON) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items. What's Next for On Holding? While On Holding has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this ...

NEW YORK--(BUSINESS WIRE)--MSCI Inc. (NYSE: MSCI) is enhancing its index calculation capabilities in alternative and multi-asset classes, including commodities and cryptocurrencies, through the acquisition of index services provider, Compass Financial Technologies. The integration of Compass builds upon MSCI's long-established roots in index innovation across public and private assets and will extend its reach across asset classes to meet growing investor demand for sophisticated, customized an. ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that its partner Pierre Fabre Pharmaceuticals (PFP) has submitted a request to the FDA for a Type A meeting. Pierre Fabre Pharmaceuticals, in partnership with Atara, submitted a briefing book to the FDA add. ...

Core Insights - Nvidia reported its fourth-quarter fiscal 2026 earnings, showcasing impressive results despite high expectations, leading to discussions about whether the stock is overvalued [1][2]. Financial Performance - Nvidia's stock price has increased by 724% over the past four years, significantly outperforming the S&P 500, Nasdaq Composite, and tech sector [2]. - The company's net income surged from less than $5 billion to $120.1 billion in four years, making it the second most profitable company globally, following Alphabet [3]. - Revenue and net income growth have outpaced stock price increases, with Nvidia converting over $0.55 of every dollar in sales into after-tax net income [3]. Revenue and Margins - Nvidia's revenue figures for fiscal years are as follows: - Fiscal 2023: $27 billion - Fiscal 2024: $60.9 billion - Fiscal 2025: $130.5 billion - Fiscal 2026: $215.9 billion - Gross margins have been strong, with figures of 56.9% in fiscal 2023, peaking at 75% in fiscal 2025, and settling at 71.1% in fiscal 2026 [4]. Future Guidance - For the first quarter of fiscal 2027, Nvidia is guiding for $78 billion in revenue and a 75% GAAP gross margin, representing a 14.5% quarter-over-quarter increase and a 76.9% increase year-over-year [5]. Customer Concentration - Nvidia's revenue is heavily reliant on a small number of customers, with the top five cloud providers accounting for over 50% of its data center revenue [6][7]. - Capital expenditure expectations from these customers have risen by nearly $120 billion since the start of 2026, approaching a total of $700 billion [7].

Core Insights - VivoSim Labs, Inc. has appointed Dr. Arumugham Raghunathan as Vice President of Global Sales to enhance commercial growth and partnerships in the biopharma sector, particularly focusing on liver and gastrointestinal toxicity solutions [1][2][3] Company Overview - VivoSim Labs, Inc. specializes in next-generation New Approach Methodologies (NAMs) for preclinical safety, utilizing three-dimensional human tissue models for liver and intestinal toxicology [7] - The company is based in San Diego, California, and aims to accelerate the adoption of human tissue models following regulatory changes favoring non-animal testing methods [7] Leadership and Strategy - Dr. Raghunathan is recognized for his ability to build consultative relationships and guide clients from pilot studies to large-scale deployments, particularly in safety assessment and decision-making [2][3] - Under his leadership, VivoSim will focus on enhancing customer engagement and delivering solutions that provide clearer insights into drug candidate toxicity, thereby improving decision-making processes [4][5] Market Demand and Services - There is a growing demand for human-relevant toxicity prediction tools, especially in the Boston area and along the East Coast, as drug development timelines shorten and modalities diversify [5] - VivoSim's services are designed to support various stakeholders, including biotech startups, large pharmaceutical companies, and academic institutions, by providing insights into liver and GI toxicity [6]

SUNNYVALE, Calif.--(BUSINESS WIRE)--Knightscope, Inc. (NASDAQ: KSCP), the security technology company building the nation's first Autonomous Security Force, today announced it has completed the acquisition of Event Risk LLC ("Event Risk†), a nationwide provider of armed and unarmed security guarding services and executive protection. Traditional guarding firms typically lack proprietary autonomous robotics and AI orchestration platforms, while technology-only vendors typically lack licensed phy. ...

Core Insights - Veritone and LeoSight have formed a strategic partnership to create a next-generation, AI-powered public safety solution that offers a cost-effective alternative to existing systems [1] - The integrated product combines Veritone's AI capabilities with LeoSight's data visualization tools to enhance real-time public safety operations [1] Company Overview - Veritone, Inc. specializes in enterprise AI and data solutions, serving various sectors including media, public sector, and talent acquisition [1] - LeoSight focuses on advanced data visualization for real-time public safety operations, enabling multi-agency collaboration and situational awareness [1] Partnership Details - The partnership aims to provide law enforcement and public safety organizations with a flexible, interoperable system that reduces reliance on single-vendor ecosystems [1] - The joint solution will facilitate critical investigations and response operations by delivering time-sensitive insights through advanced data analysis [1] Technology Integration - Veritone's AI features, such as object detection and redaction, will be integrated into the LeoSight platform, while LeoSight's visualization tools will enhance Veritone's offerings [1] - This bi-directional integration is designed to empower agencies to make faster and more accurate decisions in high-pressure situations [1] Market Positioning - The collaboration is positioned as a best-of-breed solution that is more flexible and cost-competitive compared to existing public safety technology platforms [1] - The partnership reflects a commitment to fostering innovation within an open ecosystem, allowing for greater adaptability and operational efficiency [1]

Core Viewpoint - The National Investigation Agency (NIA) of India is seeking judicial assistance from China to trace a GoPro Hero 12 Black camera linked to a terror attack in Pahalgam, which resulted in 26 fatalities and heightened tensions with Pakistan [1]. Company and Industry Summary - The GoPro HERO12 Black is a high-performance action camera designed for extreme conditions, manufactured by GoPro, Inc., an American company, but assembled in China by contract manufacturers, specifically Jabil Precision Industry (Guangzhou) Co., Ltd. [2] - The camera in question, with serial No.C3501325471706, was supplied to AE Group International Limited in China over a year prior to the Pahalgam attack, which is critical for understanding the operational preparations of the involved terrorist module [3][5]. - The NIA plans to issue a Letter Rogatory to China to identify the purchaser and end-user of the GoPro camera, following approval from a Special Court in Jammu and the Ministry of Home Affairs [4]. - GoPro BV has confirmed that the camera was activated on January 30, 2024, in Dongguan, China, but lacks downstream transaction details or end-user records [7]. - The investigation highlights the use of Chinese-origin mobile phones by terrorists involved in the attack, with two phones purchased in Pakistan, indicating a connection to cross-border terrorism facilitated by Islamabad [9].

U.S. stock futures were lower this morning, with the Dow futures falling around 800 points on Tuesday.Shares of MongoDB Inc (NASDAQ:MDB) fell sharply in pre-market trading after the company reported fourth-quarter financial results and issued first-quarter adjusted EPS guidance below estimates.MongoDB reported quarterly earnings of $1.65 per share, which beat the Street estimate of $1.45, according to Benzinga Pro. Quarterly revenue of $695.07 million beat the consensus estimate of $667.15 million and was u ...